Markers of endothelial dysfunction in patients with non‐alcoholic fatty liver disease and coronary artery disease. Issue 7 (15th July 2014)

• Record Type: Journal Article
• Authors: Elsheikh, Elzafir; Younoszai, Zahra; Otgonsuren, Munkhzul; Hunt, Sharon; Raybuck, Bryan; Younossi, Zobair M
• Is Part Of: Journal of gastroenterology and hepatology. Volume 29:Issue 7(2014:Jul.)
• Page Start: 1528
• Page End: 1534
• Publication Date: 2014-07-15
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12549
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12549-sec-0001" sec-type="section"> <title>Background</title> <p>Non‐alcoholic fatty liver disease (NAFLD) has been associated with coronary artery disease (CAD) and cardiac‐related mortality.</p> </sec> <sec id="jgh12549-sec-0002" sec-type="section"> <title>Aim</title> <p>To assess the association between endothelial dysfunction markers (Endocan, high mobility group box 1 [HMGB1], and anti‐endothelial cell antibodies [AECAs]) and the risk of CAD in NAFLD.</p> </sec> <sec id="jgh12549-sec-0003" sec-type="section"> <title>Methods</title> <p>Ninety‐one patients scheduled for coronary angiography for chest pain were included. Of these, 77 had NAFLD (85% with documented CAD). NAFLD was diagnosed after exclusion of other causes of liver diseases and by hepatic ultrasound and/or fatty liver index. Diagnosis and severity of CAD were established with coronary angiography. Endocan (ng/mL) and HMGB1 (ng/mL) concentrations were determined in the serum using enzyme‐linked immunosorbent assay technique. AECAs were quantified in sera using flow cytometry.</p> </sec> <sec id="jgh12549-sec-0004" sec-type="section"> <title>Results</title> <p>NAFLD patients with CAD had higher serum endocan level as compared with NAFLD without CAD (<italic>P</italic> = 0.006). Furthermore, levels of endocan (odds ratio [OR] 38.66 [95% confidence interval {CI} 1.10–999.99]) and hyperlipidemia (OR 5.62 [95% CI 1.36–23.19]) were significantly associated with the risk of CAD and high serum high‐density lipoprotein cholesterol level (OR 0.92 [95% CI 0.87–0.97]) was protective against CAD. On the other hand, serum level of HMGB1 was significantly lower in NAFLD patients with CAD than NAFLD patients without CAD (<italic>P</italic> = 0.0003). Interestingly, in our NAFLD cohort, serum endocan levels positively correlated the severity of CAD (<italic>r</italic> = 0.27; <italic>P</italic> < 0.05), whereas HMGB1 levels negatively correlated with severity of CAD (<italic>r</italic> = −0.35; <italic>P</italic> < 0.05). The levels of AECA were not significantly associated with CAD in NAFLD.</p> </sec> <sec id="jgh12549-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Markers of endothelial dysfunction in patients NAFLD patients may be associated with the risk for CAD.</p> </sec> </abstract>